Who is sponsoring NCT05750173?

NCT05750173 is sponsored by Institut für Pharmakologie und Präventive Medizin.

What drugs are being tested in NCT05750173?

Interventions in NCT05750173: Streamlining of the pre-procedural patient pathway.

What condition does NCT05750173 study?

NCT05750173 studies Transcatheter Aortic Valve Implantation (TAVI).

Is NCT05750173 still recruiting?

NCT05750173 is currently completed. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT05750173

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The EASE-IT CT Registry

Completed Last updated 30 March 2026

What this trial tests

trial testing Streamlining of the pre-procedural patient pathway in Transcatheter Aortic Valve Implantation (TAVI) in 150 participants. Completed in 24 March 2026.

Timeline

1 September 2023

Primary endpoint
24 March 2026

24 March 2026

Quick facts

Lead sponsor	Institut für Pharmakologie und Präventive Medizin
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 September 2023
Primary completion	24 March 2026
Estimated completion	24 March 2026
Sites	6 locations across Austria, Germany

Drugs / interventions tested

Streamlining of the pre-procedural patient pathway

Conditions studied

Transcatheter Aortic Valve Implantation (TAVI) — all drugs for Transcatheter Aortic Valve Implantation (TAVI) →

Sponsor

Institut für Pharmakologie und Präventive Medizin — full company profile →

Who can join

75 and older, any sex, with Transcatheter Aortic Valve Implantation (TAVI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ICA is not always required for a pre-TAVI workup of octogenarians and can be substituted by CTA resulting in a streamlined pre-procedural workup of patients without compromising patient safety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Transcatheter Aortic Valve Implantation (TAVI)

Currently open trials in the same condition.

NCT07469397 — Preliminary Exploration of Factors Affecting Complete Hemostasis and Supine Time After Removal of Femoral Arterial Sheat · recruiting

Other Institut für Pharmakologie und Präventive Medizin trials

Trials by the same sponsor.

NCT06953206 — Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve · not yet recruiting
NCT06702527 — Optimizing Clinical Outcomes in Patients Undergoing Mitral Transcatheter Edge-to-edge Repair (M-TEER) for Severe Functio · not yet recruiting
NCT04804748 — The DefiPace Study · recruiting
NCT04579445 — Setting a Benchmark for Resource Utilization and Quality of Care in Patients Undergoing TAVI in Europe · completed
NCT04053088 — SAVR: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting. · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05750173 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut für Pharmakologie und Präventive Medizin
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05750173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing